JPWO2020055702A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020055702A5 JPWO2020055702A5 JP2021513868A JP2021513868A JPWO2020055702A5 JP WO2020055702 A5 JPWO2020055702 A5 JP WO2020055702A5 JP 2021513868 A JP2021513868 A JP 2021513868A JP 2021513868 A JP2021513868 A JP 2021513868A JP WO2020055702 A5 JPWO2020055702 A5 JP WO2020055702A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- heavy chain
- seq
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 229940124060 PD-1 antagonist Drugs 0.000 claims 16
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 14
- 102000017578 LAG3 Human genes 0.000 claims 14
- 239000005557 antagonist Substances 0.000 claims 13
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 102000048362 human PDCD1 Human genes 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091092878 Microsatellite Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000048119 human PDCD1LG2 Human genes 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000033607 mismatch repair Effects 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730772P | 2018-09-13 | 2018-09-13 | |
| US62/730,772 | 2018-09-13 | ||
| US201862755844P | 2018-11-05 | 2018-11-05 | |
| US62/755,844 | 2018-11-05 | ||
| PCT/US2019/050122 WO2020055702A1 (en) | 2018-09-13 | 2019-09-09 | Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500410A JP2022500410A (ja) | 2022-01-04 |
| JP2022500410A5 JP2022500410A5 (https=) | 2022-09-01 |
| JPWO2020055702A5 true JPWO2020055702A5 (https=) | 2022-09-01 |
| JP7470105B2 JP7470105B2 (ja) | 2024-04-17 |
Family
ID=69776882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513868A Active JP7470105B2 (ja) | 2018-09-13 | 2019-09-09 | 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210317214A1 (https=) |
| EP (1) | EP3849606A4 (https=) |
| JP (1) | JP7470105B2 (https=) |
| AU (1) | AU2019337547A1 (https=) |
| CA (1) | CA3111066A1 (https=) |
| WO (1) | WO2020055702A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805215A1 (en) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
| KR20210088640A (ko) * | 2018-11-05 | 2021-07-14 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법 |
| MX2022012471A (es) | 2020-04-07 | 2022-11-30 | Syndax Pharmaceuticals Inc | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| TW202311262A (zh) | 2021-05-14 | 2023-03-16 | 美商錫達斯醫藥股份有限公司 | Menin-mll交互作用之抑制劑 |
| WO2023164638A1 (en) * | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
| JP2025516558A (ja) * | 2022-05-09 | 2025-05-30 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 癌治療のためのメニン－ｍｌｌ阻害剤 |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| ES2676205T3 (es) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| SG11201601763SA (en) * | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| US20170097333A1 (en) * | 2015-09-28 | 2017-04-06 | Merck Sharp & Dohme Corp. | Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| US10613092B2 (en) | 2016-04-01 | 2020-04-07 | Agilent Technologies, Inc. | Scoring methods for anti-PD therapy eligibility and compositions for performing same |
| WO2017210637A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
-
2019
- 2019-09-09 AU AU2019337547A patent/AU2019337547A1/en active Pending
- 2019-09-09 JP JP2021513868A patent/JP7470105B2/ja active Active
- 2019-09-09 CA CA3111066A patent/CA3111066A1/en active Pending
- 2019-09-09 US US17/274,531 patent/US20210317214A1/en not_active Abandoned
- 2019-09-09 WO PCT/US2019/050122 patent/WO2020055702A1/en not_active Ceased
- 2019-09-09 EP EP19859611.6A patent/EP3849606A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500410A5 (https=) | ||
| JP2017524715A5 (https=) | ||
| MX2021011500A (es) | Anticuerpos multiespecificos egfr x cd28. | |
| JP2018508483A5 (https=) | ||
| IL311603B1 (en) | Bispecific antibodies and compounds containing them for cancer treatment | |
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
| EA202190181A1 (ru) | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 | |
| JP2019519499A5 (https=) | ||
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| RU2011116112A (ru) | Биспецифические анти-egfr/анти-igf-1r антитела | |
| JP2019515008A5 (https=) | ||
| JP2019524701A5 (https=) | ||
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2018500332A5 (https=) | ||
| JP2021514973A5 (https=) | ||
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2019501973A5 (https=) | ||
| RU2014114119A (ru) | Биспецифические анти-egfr/анти igf-1r-антитела | |
| JP2020502147A5 (https=) | ||
| JPWO2020055702A5 (https=) | ||
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| JPWO2019160755A5 (https=) | ||
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 |